Thursday, October 15, 2026

Principal Financial's $37B Q1 Sales Record Widens Gap With Cost-Cutting Banks

Principal Financial Group posted record Q1 2026 investment management gross sales of $37 billion, up 21% year-over-year, while traditional banks accelerate workforce reductions ahead of a projected sub-1% GDP growth in H2 2026. Non-GAAP operating ROE expanded 140 basis points to 16.1%, underlining the fee-income advantage institutional managers hold over credit-exposed banks. Regional lenders navigating post-merger integration face a separate layer of pressure as commercial real estate prices ar

LM Salvado
LM Salvado

April 28, 2026

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Principal Financial's $37B Q1 Sales Record Widens Gap With Cost-Cutting Banks
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Principal Financial Group posted $37 billion in Q1 2026 investment management gross sales, a 21% year-over-year gain driven by strong demand for private markets and active ETFs.1 Non-GAAP operating return on equity rose 140 basis points to 16.1% in the same period.1

The numbers stand in direct contrast to the defensive posture taking hold across traditional banking. JPMorgan, Bank of America, and Société Générale are accelerating workforce reductions as GDP growth is forecast below 1% in the second half of 2026. Commercial real estate prices are projected to decline through year-end, adding pressure to lenders with concentrated CRE exposure.

Regional banks navigating post-merger integration face a distinct additional challenge. CVB Financial, absorbing Heritage Bank, reported tangible book value per share rising 9% over 12 months, from $10.45 to $11.42.2 CVB secured a sale agreement for Heritage's single-family mortgage pools, cleaning up the acquired balance sheet ahead of the expected macro slowdown.2 Capital buffers remain solid: tangible common equity at 10.5% and CET1 at 16.3%.2

Selective capital markets activity continues despite the headwinds. The SpaceX IPO and the Octave Intelligence spinoff indicate residual risk appetite remains, but concentrated in high-conviction names rather than broad deal flow.

The divergence reflects two distinct strategies consolidating across financial services. Institutional managers are capturing durable fee income by channeling client capital into private markets and active ETFs — asset classes less exposed to credit cycle volatility. Traditional banks are cutting operating costs and working through legacy integrations before the projected H2 deterioration deepens.

For institutional managers, the Q1 data suggests the model is compounding. Record gross sales alongside expanding ROE show fee-based businesses growing even as rate-sensitive bank earnings face compression. If GDP misses consensus in the back half of the year, the gap between these two halves of the financial sector will likely widen further.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleSeeking Alpha· April 23, 2026
    CVB Financial signals loan originations to hold around 6% as Heritage integration begins
  2. [2]News articleYahoo Finance· April 25, 2026
    Principal Financial Group Inc (PFG) Q1 2026 Earnings Call Highlights: Strong EPS Growth and ...
  3. [3]News articleCrunchbase News
    5 Interesting Startup Deals You May Have Missed: A Credit Card Backed By Mineral Rights, Flying Ferries, And A Foundation AI Model For Plants
  4. [4]News articleSeeking Alpha· April 24, 2026
    Ameriprise anticipates Huntington Bank onboarding to add $28B and approximately 260 advisers in Q4
  5. [5]News articleSeeking Alpha· April 10, 2026
    Catalyst Watch: Earnings heat up, Fedspeak flurry, and eyes on space
  6. [6]Press releaseGlobeNewswire· April 9, 2026
    Coface SA : Assemblée Générale Mixte du mardi 19 mai 2026 à 14h00
  7. [7]News articleSeeking Alpha· April 17, 2026
    Corporate America’s big job cuts in 2026 - What do we know so far?
  8. [8]News articleYahoo Finance· April 27, 2026
    Distribution and listing of Octave Intelligence plc
  9. [9]News articleYahoo Finance· April 26, 2026
    If You Own One of These ETFs, Fidelity Is About to Charge You $100 to Trade It
  10. [10]News articleYahoo Finance· April 2, 2026
    MetLife Investment Management Names Andrea Drasites Head of Real Estate and Agricultural Finance
  11. [11]News articleYahoo Finance· March 31, 2026
    MSCI to Reclassify the MSCI Greece Indexes from Emerging Market to Developed Market status
  12. [12]News articleYahoo Finance· April 21, 2026
    Princeton Bancorp, Inc. Announces Declaration of a $0.35 Quarterly Cash Dividend

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com